SpringerLink
Log in

Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The history of multiple weight loss medications has been a concerning paradox based on an increased cardiovascular risk despite significant reductions in adipose tissue and weight. A new class of weight loss medications could change this past narrative based on early preliminary results of cardiovascular risk (not events—still need to be determined) and weight reduction in non-diabetics that acutely competes with results achieved with bariatric surgery. The purpose of this review is to provide a comprehensive summary of the advantages and disadvantages of these newer medications, and how they could impact urology.

Recent Findings

Weight loss of − 15 to − 20% compared to baseline has become plausible in the short-term and preliminary guidance to reduce acute and chronic adverse events are receiving attention. However, the cost, access, conflicts of interest, supply chain, life-long adherence issues, and the long-term diverse implications on mental and physical health when exposed to this class of medications (GLP-1 agonists) are unknown. The profound caloric reductions should also result in baseline or ongoing nutritional deficiency testing, and general and specific dietary recommendations, which could theoretically mimic some bariatric surgery pre- and post-surgical protocols but has yet to be studied. Regardless, the potential impact of these medicines within a variety of medical specialties needs clinical research.

Summary

Current and future lifestyle interventions, dietary patterns, and medicines in the weight loss category need to be held to a paradigm whereby cardiovascular health should improve with significant weight loss without a negative impact on mental health. In urology, the ability to impact cancer risk, ED, FSD, incontinence, infertility, nephrolithiasis, and multiple other endpoints are plausible (based on bariatric surgery data) but need preliminary clinical research. Other medicines with a similar or even larger potential impact are in clinical trials, and thus, a concise overview for clinicians and researchers was needed for objective guidance. Currently, comprehensive lifestyle changes utilized with and without these medications continue to garner positive mental, physical, and legacy effects, which suggest that they are as necessary as ever in the treatment of the numerous conditions impacted by unhealthy weight gain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •  Of importance •• Of major importance

  1. Przegalinski E, Witek K, Wydra K, Kotlinska JH, Filip M. 5-HT2c receptor stimulation in obesity treatment: orthosteric agonists vs. allosteric modulators. Nutrients. 2023;15(6):1449. https://doi.org/10.3390/nu15061449.

  2. Food & Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market: potential risk of cancer outweighs the benefits. Accessed 1 Jul 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market.

  3. DiNicolantonio JJ, Chatterjee S, O’Keefe JH, Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart. 2014;1(1)e000173. https://doi.org/10.1136/openhrt-2014-000173.

  4. Garcia-Fernandez G, Krotter A, Gonzalez-Roz A, Garcia-Perez A, Secades-Villa R. Effectiveness of including weight management in smoking cessation treatments: a meta-analysis of behavioral interventions. Addict Behav. 2023;140:107606. https://doi.org/10.1016/j.addbeh.2023.107606.

  5. Tian J, Venn A, Otahal P, Gall S. The association between quitting smoking and weight gain: a systemic review and meta-analysis of prospective cohort studies. Obes Rev. 2016;17(10):1014. https://doi.org/10.1111/obr.12448.

    Article  PubMed  Google Scholar 

  6. Okorare O, Evbayekha EO, Adabale OK, Daniel E, Ubokudum D, Olusiji SA, Antia AU. Smoking cessation and benefits to cardiovascular health: a review of literature. Cureus. 2023;15(3):e35966. https://doi.org/10.7759/cureus.35966.

  7. Moyad MA. Preventing lethal prostate cancer with diet, supplements, and Rx: heart healthy continues to be prostate healthy and “first do no harm” part I. Curr Urol Rep. 2018;19:104. https://doi.org/10.1007/s11934-018-0846-4.

    Article  PubMed  Google Scholar 

  8. Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003206. https://doi.org/10.1371/journal.pmed.1003206.

  9. Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174772 participants. Lancet. 2021;397(10287):1830–41. https://doi.org/10.1016/S0140-6736(21)00591-2.

    Article  PubMed  Google Scholar 

  10. Wilson RB, Lathigara D, Kaushal D. Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. Int J Mol Sci. 2023;24(7):6192. https://doi.org/10.3390/ijms24076192.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Urquhart S, Willis S. Long-acting GLP-1 receptor agonists: findings and implications of cardiovascular outcomes trials. JAAPA. 2020;33(8):19–30. https://doi.org/10.1097/01.JA.0000669452.63883.45.

    Article  PubMed  Google Scholar 

  12. Xu D, Nair A, Sigston C, Ho C, Li J, Yang D, et al. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in nondiabetic populations. Cardiovasc Ther. 2022;2022:6820377. https://doi.org/10.1155/2022/6820377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cifuentes L, Camilleri M, Acosta A. Gastric sensory and motor functions and energy intake in health and obesity-therapeutic implications. Nutrients. 2021;13(4):1158. https://doi.org/10.3390/nu13041158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Panaro BL, Yusta B, Matthews D, Koehler JA, Song Y, Sandoval DA, Drucker DJ. Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Mol Metab. 2020;37:100990. https://doi.org/10.1016/j.molmet.2020.100990.

  15. Holst JJ, Orskov C, Hartmann B, Deacon CF. Posttranslational processing of proglucagon and postsecretory fate of proglucagon products. Front Diabetes. 1997;13:24–48. https://doi.org/10.1159/000194728.

    Article  CAS  Google Scholar 

  16. • Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022;134(supp1):5–17. https://doi.org/10.1080/00325481.2022.2147326. One of the best cumulative objective reviews of the different phase 3 trials results utilizing semaglutide.

    Article  CAS  PubMed  Google Scholar 

  17. Smith EP, Polanco G, Yaqub A, Salehi M. Altered glucose metabolism after bariatric surgery: what’s GLP-1 got to do with it? Metabolism. 2018;83:159–66. https://doi.org/10.1016/j.metabol.2017.10.014.

    Article  CAS  PubMed  Google Scholar 

  18. Tacad DKM, Tovar AP, Richardson CE, Horn WF, Krishnan GP, Keim NL, Krishnan S. Satiety associated with calorie restriction and time-restricted feeding: peripheral hormones. Adv Nutr. 2022;13(3):792–820. https://doi.org/10.1093/advances/nmac014.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hu M, Kong Z, Shi Q, Nie J. Acute effect of high-intensity interval training versus moderate-intensity continuous training on appetite-regulating gut hormones in healthy adults: a systematic review and meta-analysis. Heliyon. 2023;9(2):e13129. https://doi.org/10.1016/j.heliyon.2023.e13129.

  20. Deru LS, Chamberlain CJ, Lance GR, Gipson EZ, Bikman BT, Davidson LE, et al. The effects of exercise on appetite-regulating hormone concentrations over a 36-h fast in healthy young adults: a randomized cross-over study. Nutrients. 2023;15(8):1911. https://doi.org/10.3390/nu15081911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. touchREV Endocrinol. Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. 2022;18(1):10–9. https://doi.org/10.17925/EE.2022.18.1.10.

  22. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sorrig R, et al for the STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138–50. https://doi.org/10.1001/jama.2021.23619.

  23. Wegovy (semaglutide injection 2.4 mg) Prescribing Information. Accessed 1 Jul 2023 at https://www.novo.pi.com/wegovy.pdf.

  24. Ghusen W, De la Rose A, Sacoto D, Campos A, Feris F, Hurtado MD, Acosta A. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Network Open. 2022;5(9):e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982.

  25. •• Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64. https://doi.org/10.1111/dom.14725. One of the only studies to examine what happens when medication cessation occurs-two thirds of weight lost was regained within the first year of discontinuation.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023. https://doi.org/10.1007/s12630-023-02440-3.

    Article  PubMed  Google Scholar 

  27. Gulak MA, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. Can J Anaesth. 2023. https://doi.org/10.1007/s12630-023-02521-3.

    Article  PubMed  Google Scholar 

  28. Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091. https://doi.org/10.1016/j.jclinane.2023.111091.

  29. •• Joshi GP, Abdelmalak BB, Weigel WA, Soriano SG, Harbell MW, Kuo CI, et al. for the American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. Accessed 1 Jul 2023 at https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative. One of the only current guidelines recommendations for surgical teams dealing with patients on these novel medications.

  30. Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–9. https://doi.org/10.1111/dom.13120.

    Article  CAS  PubMed  Google Scholar 

  31. •• Gorgojo-Martinez JJ, Mazquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12:145. https://doi.org/10.3390/jcm12010145. One of the only comprehensive guides published to date on how to prevent and manage some of the most common side effects of these weight loss medications.

    Article  CAS  Google Scholar 

  32. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. https://doi.org/10.1111/dom.14551.

  33. Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R, et al. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res Care. 2020;8(2):e001706. https://doi.org/10.1136/bmjdrc-2020-001706.

  34. Zhou F, Jiang L, Jiamei G, Fan Y, Pan Q, Tianlian L, et al. Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes. Ther Adv Chronic Dis. 2023;14:20406223231161516. https://doi.org/10.1177/20406223231161516.

    Article  PubMed  PubMed Central  Google Scholar 

  35. FDA approves once-weekly Wegovy® injection for the treatment of obesity in teens aged 12 and older. Accessed 1 Jul 2024 at https://www.novonordisk-us.com/media/news-archive/news-details.html?id=151389.

  36. Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen OK, et al. for the STEP TEENS Investigators. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022. 387(24):2245–57. https://doi.org/10.1056/NEJMoa2208601.

  37. FDA approves new drug treatment for chronic weight management, first since 2014. Accessed 1 Jul 2023 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.

  38. • Kanerva N, Larrson I, Peltonen M, Lindroos A-K, Carlsson LM. Changes in total energy intake and macronutrient composition after bariatric surgery predict long-term weight outcome: findings from the Swedish Obese Subjects Study. Am J Clin Nutr. 2017;106(1):136–45. https://doi.org/10.3945/ajcn.116.149112. The main manuscript and supplementary index provide a rare glimpse into the quantity and quality of caloric intakes, which impact short and long-term weight loss after bariatric surgery.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Giusti V, Theytaz F, Di Vetta V, Clarisse M, Sutter M, Tappy L. Energy and macronutrient intake after gastric bypass for morbid obesity: a 3-y observational study focused on protein consumption. Am J Clin Nutr. 2016;103(1):18–24. https://doi.org/10.3945/ajcn.115.111732.

    Article  CAS  PubMed  Google Scholar 

  40. Reichmann MTF, Duarte A, Ivano F, Campos ACL. Evolution of the basal metabolic rate after Roux-en-Y gastric bypass: a systematic review and meta-analysis. Updates Surg. 2023. https://doi.org/10.1007/s13304-023-01523-6.

    Article  PubMed  Google Scholar 

  41. Moehlecke M, Blume CA, Rheinheimer J, Trindade MRM, Crispim D, Leitao CB. Early reduction in energy expenditure and successful weight loss after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2017;13(2):204–9. https://doi.org/10.1016/j.soard.2016.08.027.

    Article  PubMed  Google Scholar 

  42. Monnier L, Schlienger J-L, Colette C, Bonnet F. The obesity treatment dilemma: why dieting is both the answer and the problem? A mechanistic overview. Diabetes Metab. 2021;47(3):101192. https://doi.org/10.1016/j.diabet.2020.002.

  43. Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):1–7. https://doi.org/10.2337/dc22-1710.

    Article  CAS  Google Scholar 

  44. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabes Obes Metab. 2017;19(9):1242–51. https://doi.org/10.1111/dom.12932.

    Article  CAS  Google Scholar 

  45. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–62. https://doi.org/10.1111/dom.14280.

  46. Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):581–8. https://doi.org/10.1111/dom.14255.

    Article  CAS  PubMed  Google Scholar 

  47. Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes. 2023;16:575–95. https://doi.org/10.2147/DMSO.S387116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Obesity (Silver Spring). Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. 2023;31(3):703–15. https://doi.org/10.1002/oby.23673.

  49. Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023. https://doi.org/10.1172/jci.insight.170671.

    Article  PubMed  PubMed Central  Google Scholar 

  50. • Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. for the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183. Supplementary table 5 provides a unique look at the impact of this medication on fat and lean muscle mass compared to placebo.

  51. Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017;8(3):511–9. https://doi.org/10.3945/an.116.014506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. de Souza Vilela DL, da Silva A, Pinto SL, Bressan J. Relationship between dietary macronutrient composition with weight loss after bariatric surgery: a systematic review. Obes Rev. 2023;24(6):e13559. https://doi.org/10.1111/obr.13559.

  53. Reid RER, Oparina E, Plourde H, Andersen RE. Energy intake and food habits between weight maintainers and regainers, five years after Roux-en-Y gastric bypass. Can J Diet Pract Res. 2016;77(4):195–8. https://doi.org/10.3148/cjdpr-2016-013.

    Article  PubMed  Google Scholar 

  54. Moslehi N, Kamali Z, Golzarand M, Sakak FR, Mirmiran P. Association between energy and macronutrient intakes and weight change after bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2023;33(3):938–49. https://doi.org/10.1007/s11695-022-06443-9.

    Article  PubMed  Google Scholar 

  55. Bray GA, Beyond BMI. Nutrients. 2023;15(10):2254. https://doi.org/10.3390/nu15102254.

    Article  PubMed  PubMed Central  Google Scholar 

  56. American Medical Association (AMA) Press Release. AMA adopts new policy clarifying role of BMI as a measure in medicine. Accessed 1 Jul 2023 at https://www.ama-assn.org/press-center/press-releases/ama-adopts-new-policy-clarifying-role-bmi-measure-medicine.

  57. Mathus-Vliegen EMH. Obesity and the elderly. J Clin Gastroenterol. 2012;46(7):533–44. https://doi.org/10.1097/MCG.0b013e31825692ce.

    Article  PubMed  Google Scholar 

  58. Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C, Gu M. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:935823. https://doi.org/10.3389/fphar.2022.935823.

  59. Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. J Clin Med. 2023;12(3):772. https://doi.org/10.3390/jcm12030772.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Adams TD, Meeks H, Fraser A, Davidson LE, Holmen J, Newman M, et al. Long-term all-cause and cause-specific mortality for four bariatric surgery procedures. Obesity (Silver Spring). 2023;31(2):574–85. https://doi.org/10.1002/oby.23646.

    Article  CAS  PubMed  Google Scholar 

  61. Klein EA, Thompson IA Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56. https://doi.org/10.1001/jama.2011.1437.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. for the SELECT Study Group. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023;31(1):111–22. https://doi.org/10.1002/oby.23621.

  63. • Jeon E, Lee KY, Kim K-K. Approved anti-obesity medications in 2022 KSSO Guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon. J Obes Metab Syndr. 2023;32(2):106–20. https://doi.org/10.7570/jomes23032. One of the best summaries of the weight loss medication pipeline, which is replete with potential future options if efficacy and safety can be sustained.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Novo Nordisk spent $11 million on Ozempic promotion. Accessed on 1 Jul 2023 at: https://finance.yahoo.com/video/novo-nordisk-spent-11-million-155418308.html.

  65. Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss. Accessed on 1 Jul 2023 at https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss.

  66. Jung HN, Jung CH. The upcoming weekly tides (semaglutide versus tirzepatide) against obesity: STEP or SURPASS. J Obes Metab Syndr. 2022;31(1):28–36. https://doi.org/10.7570/jomes22012.

    Article  PubMed  PubMed Central  Google Scholar 

  67. le Roux CW, Hankosky ER, Wang D, Malik R, Yu M, Hickey A, et al. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison. Diabetes Obes Metab. 2023. https://doi.org/10.1111/dom.15148.

  68. Azuri J, Hammerman A, Aboalhasen E, Sluckis B, Arbel R. Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis. Obesity (Silver Spring). 2023;31(6):1510–3. https://doi.org/10.1002/oby.23752.

    Article  CAS  PubMed  Google Scholar 

  69. Clinicaltrials.gov. A study of tirzepatide (LY3298176) in participants with obesity or overweight with weight related comorbidities (SURMOUNT-5). Accessed on 1 Jul 2023 at: https://classic.clinicaltrials.gov/ct2/show/NCT05822830?term=NCT05822830&draw=2&rank=1.

  70. Block J. Eli Lilly to use priority review voucher for Mounjaro weight loss indication. https://seekingalpha.com/news/3961462-eli-lilly-priority-review-voucher-mounjaro-weight-loss-indication.

  71. Sarpatwari A, Kesselheim AS. Efficacy of the priority review voucher program. JAMA. 2016;315(15):1660–1. https://doi.org/10.1001/jama.2016.0386.

    Article  PubMed  Google Scholar 

  72. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the surgical weight loss patient 2016 update: micronutrients. Surg Obes Relat Dis. 2017;13(5):727–41. https://doi.org/10.1016/j.soard.2016.12.018.

    Article  PubMed  Google Scholar 

  73. O’Kane M, Parretti HM, Pinkney J, Welbourn R, Hughes CA, Mok J, et al. British Obesity and Metabolic Surgery Guidelines for perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery—2020 update. Obes Rev. 2020;21(11):e13087. https://doi.org/10.1111/obr.13087.

  74. Blum D. An extreme risk in taking Ozempic: malnutrition: the diabetes medication has gained attention for its dramatic weight loss effects-but doctors worry that it can go too far. Accessed on 1 Jul 2023 at: https://www.nytimes.com/2023/04/21/well/eat/ozempic-side-effects-malnutrition.html.

  75. Desai D, Singhal S, Koka J. Evaluating the correlation of bariatric surgery and the prevalence of cancers in obese patients: a study of the National Inpatient Sample Database. Cureus. 2022. 14(4):e23976. https://doi.org/10.7759/cureus.23976.

  76. Aminian A, Wilson R, Al-Kurd A, Tu C, Milinovich A, Kroh M, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022;327(24):2423–33. https://doi.org/10.1001/jama.2022.9009.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63(11):3891–905. https://doi.org/10.2337/db13-1169.

    Article  CAS  PubMed  Google Scholar 

  78. Malczak P, Wysocki M, Pisarska-Adamczyk M, Strojek J, Rodak H, Lastovetskyi I, et al. Influence of bariatric surgery on erectile dysfunction-a systematic review and meta-analysis. Obes Surg. 2023;33(6):1652–8. https://doi.org/10.1007/s11695-023-06572-9.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Loh HH, Shahar MA, Loh HS, Yee A. Female sexual dysfunction after bariatric surgery in women with obesity: a systematic review and meta-analysis. Scand J Surg. 2022;111(1):14574969211072396. https://doi.org/10.1177/14574969211072395.

    Article  PubMed  Google Scholar 

  80. King WC, Hinerman AS, Subak LL. Seven-year durability of improvements in urinary incontinence after Roux-en-Y gastric bypass and sleeve gastrectomy. JAMA Netw Open. 2022. 5(12):e2246057. https://doi.org/10.1001/jamanetworkopen.2022.46057.

  81. Lee Y, Yu J, Tikkinen KAO, Pedziwiatr M, Major P, Aditya I, et al. The impact of bariatric surgery on urinary incontinence: a systematic review and meta-analysis. BJU Int. 2019;124(6):917–34. https://doi.org/10.1111/bju.14829.

    Article  PubMed  Google Scholar 

  82. Muller RL, Gerber L, Moreira DM, Andriole Jr G, Hamilton RJ, Fleshner N, et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol. 2013;63(6):111es 5–1121. https://doi.org/10.1016/j.eururo.2013.02.038.

  83. Nosrati F, Nikoobakht MR, Oskouie IM, Rahimdoost N, Inanloo H, Abolhassani M, et al. Does significant weight loss after bariatric surgery affect sexual function and urinary symptoms? An Iranian Study Obes Surg. 2023. https://doi.org/10.1007/s11695-023-06717-w.

    Article  PubMed  Google Scholar 

  84. Stefanova I, Currie AC, Newton RC, Albon L, Slater G, Birnie A, et al. Systematic review and meta-analysis of the impact of bariatric surgery on lower urinary tract symptoms in males. Obes Surg. 2021;31(7):3151–8. https://doi.org/10.1007/s11695-021-05403-z.

    Article  PubMed  Google Scholar 

  85. Lee Y, Dang JT, Switzer N, Yu J, Tian C, Birch DW, Karmali S. Impact of bariatric surgery on male sex hormones and sperm quality: a systematic review and meta-analysis. Obes Surg. 2019;29(1):334–46. https://doi.org/10.1007/s11695-018-3557-5.

    Article  PubMed  Google Scholar 

  86. Gao Z, Liang Y, Yang S, Zhang T, Gong Z, Li M, Yang J. Bariatric surgery does not improve semen quality: evidence from a meta-analysis. Obes Surg. 2022;32(4):1341–50. https://doi.org/10.1007/s11695-022-05901-8.

    Article  PubMed  Google Scholar 

  87. Moxthe LC, Sauls R, Ruiz M, Stern M, Gonzalvo J, Gray HL. Effects of bariatric surgeries on male and female fertility: a systematic review. J Reprod Infertil. 2020;21(2):71–86. https://pubmed.ncbi.nlm.nih.gov/32500010/.

  88. Alibhai KM, Churchill IF, Vause T, Lochnan HA. The impact of bariatric surgery on assisted reproductive technology outcomes: a systematic review. J Obstet Gynaecol Can. 2022;44(8):915–23. https://doi.org/10.1016/j.jogc.2022.04.010.

    Article  PubMed  Google Scholar 

  89. Laurenius A, Sundbom M, Ottosson J, Naslund E, Stenberg E. Incidence of kidney stones after metabolic and bariatric surgery—data from the Scandinavian Obesity Surgery Registry. Obes Surg. 2023;33(5):1564–70. https://doi.org/10.1007/s11695-023-06561-y.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Thongprayoon C, Cheungpasitporn W, Vijayvargiya P, Anthanont P, Erikson SB. Ren Fail. The risk of kidney stones following bariatric surgery: a systematic review and meta-analysis. 2016;38(3):424–30. https://doi.org/10.3109/0886022X.2015.1137186.

    Article  Google Scholar 

  91. Helmen ZM, Helm MC, Helm JH, Nielsen A, Kindel T, Higgins R, et al. Predictors of postoperative urinary tract infection after bariatric surgery. Obes Surg. 2018;28(7):1950–4. https://doi.org/10.1007/s11695-017-3095-6.

    Article  PubMed  Google Scholar 

  92. Arafat M, Norain A, Burjonrappa S. Characterizing bariatric surgery utilization and complication rates in the adolescent population. J Pediatr Surg. 2019;54(2):288–92. https://doi.org/10.1016/j.pedsurg.2018.10.089.

    Article  PubMed  Google Scholar 

  93. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin—a case series. Ther Adv Psychopharmacol. 2023. https://doi.org/10.1177/20451253231165169.

  94. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. for the GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2302392.

  95. Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. for the Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2301972.

  96. Knop FK, Aroda V, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023. https://doi.org/10.1016/S0140-6736(23)01185-6.

  97. Terhune C for Reuters. Exclusive: most patients using weight loss drugs like Wegovy stop within a year, data show. Accessed on 11 Jul at: https://www.reuters.com/business/healthcare-pharmaceuticals/most-patients-using-weight-loss-drugs-like-wegovy-stop-within-year-data-show-2023-07-11/.

  98. Reuters and NBC News. EU investigates Ozempic and weight-loss drug Saxenda after reports of suicidal thoughts. Accessed 11 Jul 2023 at: https://www.nbcnews.com/news/world/eu-investigates-ozempic-saxenda-suicidal-thoughts-reported-rcna93552.

  99. Hartmann-Boyce J, Theodoulou A, Oke JL, Butler AR, Bastounis A, Dunnigan A, et al. Long-term effect of weight regain following behavioral weight management programs on cardiometabolic disease incidence and risk: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2023;16(4):e009348. https://doi.org/10.1161/CIRCOUTCOMES.122.009348.

  100. Theodoulou A, Hartmann-Boyce J, Gorenberg J, Oke JL, Butler AR, Bastounis A, et al. Weight regain and mental health outcomes following behavioural weight management programmes: a systematic review and meta-analyses. Clin Obes. 2023. 13(3):e12575. https://doi.org/10.1111/cob.12575.

  101. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 374(9702):1677–86. https://doi.org/10.1016/S0140-6736(09)61457-4.

  102. Vinas Esmel E, Naval Alvarez J, Sacanella ME. The legacy effect in the prevention of cardiovascular disease. Nutrients. 2020;12(11):3227. https://doi.org/10.3390/nu12113227.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Johnson JL, Slentz CA, Ross LM, Huffman KM, Kraus WE. Ten-year legacy effects of three eight-month exercise training programs on cardiometabolic health parameters. Front Physiol. 2019;10:452. https://doi.org/10.3389/fphys.2019.00452.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA

    Mark A. Moyad

Authors
  1. Mark A. Moyad
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Mark A. Moyad, MD, MPH conceived and wrote the main manuscript and procured, reviewed, and inserted the references.

Corresponding author

Correspondence to Mark A. Moyad.

Ethics declarations

Competing Interests

Dr. Moyad was a quality control consultant for Max International Beauty (Cosmetics).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moyad, M.A. Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.). Curr Urol Rep 24, 515–525 (2023). https://doi.org/10.1007/s11934-023-01180-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-023-01180-7

Keywords

Search

Navigation